A new study published in The American Journal of Human Genetics reveals how centuries of colonial expansion and the Indian Ocean slave trade shaped South Africa’s genetic landscape, leaving a profound legacy of sex-biased admixture.
Researchers analyzed genetic data from over 1,400 individuals across South Africa to understand how migration and displacement transformed Indigenous communities. The findings show that European male settlers contributed disproportionately to genetic lineages, while Khoe-San women and enslaved women from South and Southeast Asia made major contributions to the maternal gene pool.
Interestingly, while genetic mixing around the Cape was continuous, northern Khoe-San communities experienced a single pulse of European admixture about six to eight generations ago. The Nama people showed unique founder effects, with about 15% of Y-chromosome lineages tracing back to Asia, reflecting the deep genetic impact of forced migrations during colonial times.
This research highlights how genomics can uncover stories of resilience and connection, offering new insight into Africa’s intertwined histories of movement, survival, and identity.
At MyAfroDNA, we are committed to advancing genomics research by providing high-quality African biospecimens and molecular testing services that help decode Africa’s diverse genetic heritage.
Click here for further reading.
In a recent Nature Communications article, Alex M. Vakulskas, Andrew P. Goodman, Paola S. Guerena, William L. Hsieh, Benjamin M. Lane, Joseph N. Blattman, John L. Rinn, and Silvana Konermann present an innovative approach to overcoming one of the biggest challenges in epigenome editing: efficient delivery.
The team developed RENDER (Robust ENveloped Delivery of Epigenome-editor Ribonucleoproteins), a platform that packages CRISPR-based epigenome editors into engineered virus-like particles (eVLPs). Unlike viral vectors or plasmid delivery, which can pose risks of integration and cytotoxicity, RENDER delivers the editors as transient ribonucleoproteins (RNPs), ensuring high specificity and reduced off-target effects.This system was tested across a range of cell types, including iPSC-derived neurons and primary human T cells, showing durable gene silencing from a single treatment.
Remarkably, when applied to neurons carrying the MAPT V337M mutation, RENDER reduced Tau protein expression by more than 60% — a proof-of-concept with implications for treating neurodegenerative diseases.The ability to deliver programmable epigenome editors safely, transiently, and effectively represents a leap forward for gene regulation therapies. With continued optimization, this platform could accelerate progress in epigenetic drug development and broaden research applications. Click here for further reading.
At MyAfroDNA, we understand the importance of access to quality African biospecimens and molecular testing for advancing biomedical innovations like these. Partner with us to power your next research breakthrough.
A new study introduces the South African Blood Regulatory (SABR) resource, a functional genomics dataset derived from >600 individuals from three South Eastern Bantu-speaking populations (Pedi/Bapedi, Tsonga, Zulu). The project integrates whole-genome sequencing and blood transcriptome data to map regulatory variation (expression QTLs / splice QTLs / cell-type interaction QTLs) for 40 blood-cell traits. One major finding: many regulatory variants are unique to individuals of African ancestry, and a substantial fraction are entirely absent in non-African populations.
Compared to the widely used GTEx project (which is heavily biased toward European ancestry), SABR detects more regulatory variants per gene—even though the sample size is smaller. The team also utilizes GWAS summary statistics from African-ancestry participants in the Pan-UK Biobank to demonstrate that SABR enhances the interpretation of genetic associations, specifically identifying putative causal genes and mechanisms linked to blood-related traits and disease risks that would otherwise be more difficult to discern.
SABR’s analysis connects changes in blood cell subtype levels with diseases like HIV, obesity, hypertension, asthma, and the effects of smoking. Several variants that influence disease-relevant cell types or levels are common in SABR but rare or unobserved elsewhere. The full SABR summary statistics are being made publicly available to support researchers.
Read the full article here
Antimicrobial resistance (AMR) poses a major threat to global health, and Africa is no exception. As pathogens evolve, our ability to treat common infections is becoming increasingly limited.
A new study published in Scientific Reports provides valuable insight into the genetic basis of AMR in Africa, focusing on Staphylococcus aureus, one of the most widespread and clinically significant bacteria.What the Study FoundResearchers analyzed 95 whole genomes of S. aureus collected from 11 African countries. The majority of these samples were human-derived, taken from blood, pus, urine, and wound sites.
Through bioinformatic analysis, they identified 33 antimicrobial resistance genes.Key findings include:Efflux pump mechanisms were the dominant form of resistance, allowing bacteria to actively expel antibiotics.Other resistance strategies included enzyme-mediated inactivation, target alteration, protection, and replacement.West and East Africa emerged as hotspots for the distribution of resistance genes, signaling the need for stronger surveillance in these regions.
These findings highlight the urgent need to expand genomic surveillance systems across the continent. Despite covering 11 countries, the study was limited by small sample sizes and lack of data from many African nations. This gap emphasizes the importance of building local capacity for sequencing, data analysis, and sample collection.For African health systems, this research serves as a reminder that combating AMR requires both global collaboration and homegrown solutions. Without comprehensive genomic data, it will be difficult to design effective treatment guidelines, track the spread of resistance, or prepare for future outbreaks.
At MyAfroDNA, we believe genomic research should be powered by African data, African expertise, and African innovation. Our mission is to provide high-quality biospecimens and molecular testing services that enable researchers to generate the insights needed to safeguard public health.AMR is a collective challenge, but with better data and stronger collaboration, Africa can take the lead in finding solutions.
Read the full publication here: https://www.nature.com/articles/s41598-025-01398-0
A groundbreaking study published in Nature Communications has revealed novel genetic variants associated with carotid intima-media thickness (cIMT), a key marker of early atherosclerosis, among nearly 8,000 adults from sub-Saharan Africa. The research, part of the AWI-Gen project, included participants from Burkina Faso, Ghana, Kenya, and South Africa and marks one of the largest genome-wide association studies (GWAS) on cardiovascular risk in African populations.
Two previously unidentified loci, SIRPA and FBXL17, were found to be significantly associated with cIMT, offering new insight into biological pathways involved in vascular health. Notably, the study also identified sex-specific genetic signals: SNX29 in men, and LARP6 and PROK1 in women, the latter two being enriched for estrogen response genes. These findings suggest different genetic mechanisms for cardiovascular risk between men and women.
Many of the variants identified in this African cohort are either rare or absent in European populations, emphasizing the critical need for diversity in genomic research. This study not only deepens our understanding of cardiovascular disease in African communities but also underscores the importance of building inclusive datasets to drive precision medicine. At MyAfroDNA, we champion this kind of Africa-led genomic science.
Read more on this research here: https://www.nature.com/articles/s41467-022-28276-x
A groundbreaking pair of studies published in Antiquity reveals compelling genetic evidence of West African ancestry in two individuals buried in seventh-century England. The first “West African ancestry in seventh-century England: two individuals from Kent and Dorset” was led by Professor Duncan Sayer of the University of Central Lancashire, examining the female burial from Updown, Kent.
The second, focusing on the male burial at Worth Matravers, Dorset, titled Ancient genomes reveal cosmopolitan ancestry and maternal kinship patterns at post-Roman Worth Matravers, Dorset, was led by Dr. Ceiridwen J. Edwards from the University of Huddersfield.
In both cases, mitochondrial DNA traced maternal lineage to Northern Europe, while autosomal DNA showed clear affinity with present-day Yoruba, Mende, Mandenka, and Esan groups, indicating a West African paternal grandparent.
The Updown burial included a Frankish pot and spoon suggestive of Christian or Byzantine connections, highlighting continental ties, whereas the Dorset individual was interred with local artifacts and a burial companion, underscoring full local integration.
These discoveries represent the first genetic proof of sub-Saharan African connections in Early Medieval Britain, reshaping our understanding of migration, identity, and social complexity in that era.
Read more about this discovery here.
Location: Port Harcourt, Nigeria (Hybrid)
Organization: MyAfroDNA – Advancing African Genomics and Molecular Research
Type: Full-time | Contract | Onsite
About Us
MyAfroDNA is a pioneering biotech dedicated to providing African biospecimens, molecular testing, and CRO services to support global research, public health, and innovation. From paternity testing to biospecimen analysis, we are committed to delivering high-quality scientific services.
Role Overview
We are looking for a dynamic Field Application Scientist to serve as a liason between our laboratory team and external stakeholders. This role is ideal for someone passionate about genomics, diagnostics, and community-focused science, with a talent for building relationships, developing partnerships, and driving client engagement.
Key Responsibilities
- Promote MyAfroDNA’s services to research institutions, hospitals, NGOs, and private clients.
- Identify and develop partnerships with universities, labs, and health organizations.
- Conduct field visits to introduce our services and collect feedback.
- Represent MyAfroDNA at events, conferences, and local exhibitions.
- Collaborate with the product team to ensure client needs inform service development.
- Provide input on marketing strategy from a scientific and community-focused lens.
Requirements
- Background in Biology, Biotechnology, Public Health, or a related field.
- Strong communication, networking, and presentation skills.
- Familiarity with molecular testing and biospecimen collection.
- Experience working with communities, NGOs, or research teams is a plus.
- Willingness to travel within Nigeria and beyond as needed.
Bonus Skills
- Community Engagement
- Experience with grant writing or science communication
- Previous work in a startup or research outreach
How to Apply
Please complete the application form using this link and upload your CV and cover letter.
A comprehensive genomic study of 208 neonatal Escherichia coli isolates collected from 2012 to 2021 at a major hospital in Blantyre, Malawi found extensive diversity in sequence types (STs), O‑antigens, and H‑antigens among strains causing invasive disease . Genomes from 169 isolates passed quality control and revealed 71 distinct STs, including 11 previously unreported types; over half of STs were observed only once . Among common lineages, ST69, ST131, ST10, and ST410 were most frequent, with ST410 highly enriched in cerebrospinal fluid samples suggesting invasive potential .
Researchers also catalogued 63 O‑antigen types—none exceeding 10% prevalence—and 34 H‑types, with only a handful appearing in more than one year. Notably, serotypes O15, O25B, and O8 appeared most often but no type dominated across years .
Using theoretical vaccine coverage models, the study shows that existing vaccine candidates like EXPEC4V or EXPEC9V would leave a large proportion of isolates unprotected. Crucially, the removal of O8 from some vaccine formulations could significantly reduce coverage in this setting .
Additionally, high resistance rates were observed: over 90% of strains demonstrated resistance to co‑trimoxazole, and many were multidrug resistant; yet meropenem resistance remained rare. Only amikacin and carbapenems remained reliable options in severe cases .
Implications for vaccine design in sub‑Saharan Africa: The extraordinary antigenic diversity among neonatal E. coli in Malawi presents a significant obstacle to one‑size‑fits‑all O‑antigen vaccines. The authors recommend vaccine strategies tailored to local serotype ecology and genetic surveillance integrated into design efforts.
Read more here.
A new study published by our partners, the AfricaBP Open Institute, showcases transformative efforts to harness biodiversity genomics and bioinformatics to drive a sustainable African bioeconomy.
The Africa BioGenome Project (AfricaBP) aims to sequence 105,000 non‑human genomes across Africa, spanning plants, animals, fungi, and protozoa, to support food security, conservation, and biotech innovation. To bridge capacity gaps, the AfricaBP Open Institute organized 31 hands‑on regional workshops in 2024 across five geographic regions, engaging participants from over 50 African countries. These sessions trained 401 African researchers in genome sequencing, gene editing, bioinformatics, molecular biology, ethics, and biobanking, strengthening local research infrastructure and skills.
A highlight case study: the proposed “1000 Moroccan Genome Project,” which illustrates economic returns from local genome sequencing. Analysis shows that a US$20 million investment over 10 years could yield US$40 million in discounted benefits and deliver a benefit–cost ratio (BCR) of 3.29—meaning every dollar invested returns more than three dollars in value—particularly across agriculture, R&D, education, and downstream sectors.
Key recommendations emerge: integrate biodiversity genomics and bioinformatics into national bioeconomy strategies, expand capacity‑building initiatives, build regional sequencing hubs, and foster ethical, inclusive data-sharing policies. Strategic investment in these domains positions African nations to capitalize on their unique biodiversity and reclaim ownership of genomic science—a powerful lever toward sustainable development and regional innovation rooted in African knowledge and priorities .
In short, AfricaBP’s model provides a scalable path for leveraging genomic science to fuel a resilient, inclusive African bioeconomy driven by regional talent and locally generated data. Read more here.